{"altmetric_id":7309892,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Hoffmann-La Roche"],"first_seen_on":"2016-05-10T09:47:13+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1462817306,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02701985"],"nct_id":"NCT02701985","pubdate":"2016-03-03T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":7672691,"mean":6.5915218985731,"rank":1056911,"this_scored_higher_than_pct":85,"this_scored_higher_than":6547345,"rank_type":"exact","sample_size":7672691,"percentile":85},"similar_age_3m":{"total_number_of_other_articles":267459,"mean":11.429298865616,"rank":53801,"this_scored_higher_than_pct":78,"this_scored_higher_than":209898,"rank_type":"exact","sample_size":267459,"percentile":78},"this_journal":{"total_number_of_other_articles":20652,"mean":10.075194808968,"rank":3374,"this_scored_higher_than_pct":75,"this_scored_higher_than":15539,"rank_type":"exact","sample_size":20652,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":963,"mean":13.706353430353,"rank":115,"this_scored_higher_than_pct":75,"this_scored_higher_than":730,"rank_type":"exact","sample_size":963,"percentile":75}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["pm_360"],"posts_count":1}},"posts":{"news":[{"title":"TRACTISS ends rituximab hopes for Sj\u00f6gren\u2019s syndrome","url":"http:\/\/ct.moreover.com\/?a=26471876036&p=1pl&v=1&x=QrROoxMbPbGkv6pTw9-GSQ","license":"public","citation_ids":[2054149,1639832,1987838,7309892,7309893,4685087,7309894],"posted_on":"2016-05-09T18:08:26+00:00","summary":"AT RHEUMATOLOGY 2016 GLASGOW (FRONTLINE MEDICAL NEWS) \u2013 Rituximab is unlikely to work as a treatment for Sj\u00f6gren\u2019s syndrome, according to a sneak peak of results from a multicenter study.","author":{"name":"PM 360","url":"http:\/\/www.pm360online.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/739\/normal\/Screen_Shot_2016-02-02_at_17.08.15.png?1454432906"}}]}}